Minocycline for the Prevention of Post-operative Intercostal Neuralgia
Unknown statusPhase 2NCT01314482
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
In about half the patients who have an open chest surgery there is persistent severe pain in the chest. The investigators are examining whether minocycline, a commonly used antibiotic, will prevent pain. Minocycline blocks the activity of immune cells which the investigators believe are responsible for prolonging the pain.
Study details
- Official title
- The Efficacy of Prophylactic Administration of Minocycline in Reducing Chronic Intercostal Neuralgia Post-thoracotomy
- Conditions
- Post-operative Intercostal Neuralgia
- Interventions
- Drug: Minocycline
- Sponsor
- University of Adelaide
- Start date
- 2010-11
- Primary completion
- 2013-12
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Australia
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or female * Aged 18 years or older * Undertaking elective, open thoracotomy with ample time pre-operatively to provide informed consent and undertake dosing * Sufficient fluency in English language to read and understand consent form, fulfil study requirements and communicate with research staff * Negative pregnancy test at screening for women of child bearing potential * Females of child bearing potential must agree to use a medically acceptable method of contraception other than oral contraceptives from time of first dosing until one week post-operatively. Acceptable methods include abstinence, contraceptive patches, NuvaRing (etonogestrel/ethinyl oestradiol vaginal ring), diaphragm with vaginal spermicide, intrauterine device, condom and vaginal spermicide, progestin implant or injection * Avoid prolonged, direct sunlight or ultra-violet light exposure during dosing period * Refrain from strenuous activities and avoid changes to regular exercise patterns throughout trial period Exclusion Criteria: * Pregnant or breast feeding * Known allergy to minocycline and other tetracycline antibiotics * Pre-existing neuralgic pain condition in area designated for operation * Physical abnormality in area designated for operation * Taking disallowed concomitant medication * Renal insufficiency as determined by a calculated creatinine clearance of \< 60mL/min * Hepatic dysfunction as determined by alanine transaminase and/or aspartate transaminase in excess of three times upper normal limits * Diagnosis of systemic lupus erythematosus * Recent diagnosis of enterocolitis or colitis * Participation in another trial of an investigational product within 30 days of commencing dosing or are scheduled to commence trial of an investigational product during study period * Patients who, in an Investigator's opinion, should not participate in the trial or may not be capable of following the trial schedule for any reason * History of major psychiatric disorder not medically controlled
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01314482